In conclusion, in this multicenter, retrospective cohort study, LCT was found to prolong PFS and OS in patients with advanced lung adenocarcinomas, who were harboring susceptible EGFR mutations and treated with first-line afatinib. Here, EGFR is linked to lung adenocarcinoma.